Robert Wessman CEO of Iceland-based generic pharmaceuticals company Actavis announced in an interview with Bloomberg yesterday that Actavis is making bids for Romanian pharmaceuticals company Antibiotice.
Wessman explained that Actavis is among 22 companies making bids for a 53 percent share in Antibiotice, which has a nine percent market share in Romania. Actavis currently has an eight percent share of the Romanian market. Fréttabladid reports.
According to Landsbankinn bank the market value of Antibiotice is ISK 21 billion (EUR 228 million, USD 302 million).
Wessman said the price is likely to rise as so many companies are making bids for Antibiotice. In that case, Wessman said, Actavis will withdraw its bid.
Actavis recently acquired 51 percent of shares in Russian pharmaceutical manufacturer ZiO Zdorovje. For further information, click here.